1020315-31-4 | 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$31.00	$22.00
10mg	98%	in stock	$44.00	$31.00
25mg	98%	in stock	$87.00	$61.00
50mg	98%	in stock	$148.00	$103.00
100mg	98%	in stock	$216.00	$152.00
250mg	98%	in stock	$384.00	$269.00

Description

• Catalog Number: AA08102
• Chemical Name: 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
• CAS Number: 1020315-31-4
• Molecular Formula: C23H20F3N5O2
• Molecular Weight: 455.4324095999999
• MDL Number: MFCD18782721
• SMILES: O=C(N1CCC(=Cc2cccc(c2)Oc2ccc(cn2)C(F)(F)F)CC1)Nc1cccnn1

Computed Properties

• Complexity: 680
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.3

Upstream Synthesis Route

$Name$ is a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which plays a crucial role in regulating intracellular levels of cyclic nucleotides cAMP and cGMP. In chemical synthesis, PF04457845 is utilized as a valuable tool compound for studying the physiological functions of PDE10A and exploring its potential as a therapeutic target in various diseases such as neurodegenerative disorders and psychiatric conditions. By inhibiting PDE10A, PF04457845 can modulate cellular signaling pathways that are involved in neurotransmission, neuronal development, and synaptic plasticity, offering insights into the molecular mechanisms underlying these processes. This compound exhibits high potency and selectivity for PDE10A, making it a valuable asset for research purposes in the field of chemical synthesis and drug discovery.

Literature

• Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.

  Science (New York, N.Y.) 20170609

• Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20140214

• Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.

  The Proceedings of the Nutrition Society 20140201

• An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.

  Pain 20120901

• Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.

  British journal of clinical pharmacology 20120501

• Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.

  Pharmacological research 20120501

• Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.

  The Journal of pharmacology and experimental therapeutics 20110701

• Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

  ACS medicinal chemistry letters 20110210

• Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.

  International review of psychiatry (Abingdon, England) 20090401